Navigation Links
Schering-Plough Reports Financial Results for 2009 Second Quarter
Date:7/21/2009

llions) (unaudited) ----------- 2009 2008 % ---- ---- - Net sales, as reported $9,040 $9,577 (6%) 50 percent of cholesterol joint venture net sales a/ 975 1,174 (17%) --- ----- ---- Adjusted net sales $10,015 $10,751 (7%) ======= ======= === a/ Total Net sales of the cholesterol joint venture for the three months ended June 30, 2009 and 2008 were $1.0 billion and $1.1 billion, respectively. Total Net sales of the cholesterol joint venture for the six months ended June 30, 2009 and 2008 were $1.9 billion and $2.3 billion, respectively. NOTE: Adjusted net sales, defined as net sales plus an assumed 50 percent of global cholesterol joint venture net sales, is a non-U.S. GAAP measure used by management in evaluating the performance of the Schering-Plough's overall business. Schering-Plough believes that this performance measure contributes to a more complete understanding by investors of the overall results of the company. Schering-Plough provides this information to supplement the reader's understanding of the importance to the company of its share of results from the operations of the cholesterol joint venture. Net sales (excluding the cholesterol joint venture net sales) is required to be presented under U.S. GAAP. The cholesterol joint venture's net sales are included as a component of income from operations in the calculation of Schering-Plough's "Equity income." Net sales of the cholesterol joint venture do not include
'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Based on the revenues gained from surgical ... dominated by four major players contributing to approximately ... include GE Healthcare (U.K.), Siemens AG (Germany), Philips ... Report Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html , The ... to its strong product portfolio, which includes its ...
(Date:12/17/2014)... Beach, CA (PRWEB) December 17, 2014 ... Inc. to provide a larger packaged waste water treatment ... in King Abdullah Economic City (KAEC). Two years ago ... EMAAR’s Jeddah Gate Development, serving two residential towers with ... capacity is over a quarter million gallons per day ...
(Date:12/17/2014)... Diego, CA (PRWEB) December 17, 2014 ... and activation agency and member of the Huntsworth Health ... Gonzales to its executive team. In her role, Gonzales ... , “We are incredibly honored to welcome a ... Agency Chief and CEO, Gaëtan Fraikin. “She is a ...
(Date:12/17/2014)... Dec. 17, 2014 Tigercat Pharma, Inc. ... study evaluating the investigational oral NK-1 receptor antagonist ... severe, chronic itch who are unresponsive or inadequately ... topical steroids and antihistamines. The ... Analog Scale (VAS) itch score from baseline, comparing ...
Breaking Biology Technology:Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
... Draws Participants From A Broad Range of Industries Despite ... edition of InformexUSA officially opened its exhibition floors Wednesday ... show traffic in 2008. The week long exhibition & ... in North America, is featuring an expanded program to ...
... Mass., Jan. 29 Repligen Corporation (Nasdaq: ... Chief Executive Officer, Walter C. Herlihy, Ph.D., will host ... 2009 at 10:00 a.m. EST, to report third quarter ... quarterly update of the Company.This call is being webcast ...
... 29, 2009 Senomyx, Inc. (Nasdaq: SNMX ) ... fiscal year ending December 31, 2008 on Thursday, February 12, ... The Company will also host a conference call and live ... Time) that same day. During the call, Senomyx,s management ...
Cached Biology Technology:InformexUSA 2009 Opens to Strong Attendance 2InformexUSA 2009 Opens to Strong Attendance 3InformexUSA 2009 Opens to Strong Attendance 4Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results 2Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results 3SENOMYX, INC. fourth quarter AND FISCAL YEAR-END 2008 Earnings conference call scheduled for February 12, 2009 2
(Date:11/18/2014)... -- The Secure Identity & Biometrics Association (SIBA) and ... formation of The Airport Entry and Exit Working ... Biometric Entry and Exit Solutions Framework for Airports ... BORDERPOL, the international non-profit organization that works directly ... border security, traveler and migration systems. ...
(Date:11/15/2014)... YORK , Nov. 13, 2014  While we may ... technology Doctor McCoy used in "Star Trek" to gain instant ... tools designed to work with smartphones and tablets for monitoring ... of the healthcare world. This may seem a tad Orwellian ... ready to adopt some of these technological opportunities into their ...
(Date:11/7/2014)... led by Dr. Debra Auguste, associate professor, biomedical ... The City College of New York, have identified ... for one of the most aggressive forms of ... have a high mortality rate owing to aggressive ... therapeutic options. However, Professor Auguste,s team, discovered the ...
Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... rich in omega-3 fatty acids can inhibit growth of breast ... from the University of Guelph. The study, published recently ... to be the first to provide unequivocal evidence that omega-3s ... Ma, a professor in Guelph,s Department of Human Health and ...
... Washington, DC The Entomological Society of America (ESA) ... today a new partnership that will provide ESA members ... policy debates. The ESA is the ... scientific needs of entomologists and individuals in related disciplines. ...
... of Southampton have identified the molecular system that ... brain during neurodegenerative diseases. An important aspect ... Huntington,s or prion disease, is the generation of ... Results from the study open new avenues ...
Cached Biology News:Omega-3s inhibit breast cancer tumor growth, study finds 2Entomological Society of America launches science policy program 2Scientists identify molecular system that could help develop treatments for Alzheimer's disease 2
Recorder, 6", 7 Day, 1 Pen, 0 to 100°C, 220V, 50/60 Hz, for 4520, Customer Installed...
... Serotec STAR3000 HISTAR detection systems ... to be used with species specific ... in tissue specimens. Visualisation is accomplished ... that utilises novel polymer labelling technology. ...
Taq DNA Polymerase (T. aquaticus), 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzyme...
... Polymerase is the most thoroughly characterized enzyme ... to its overall utility and efficacy. , ... for PCR applications. , It is ... ,, AmpliTaq DNA Polymerase is a 94 ...
Biology Products: